Related references
Note: Only part of the references are listed.Bruton's TK regulates myeloid cell recruitment during acute inflammation
Gareth S. D. Purvis et al.
BRITISH JOURNAL OF PHARMACOLOGY (2022)
Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis
Brian T. Hopkins et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Discovery of KRas G12C-IN-3 and Pomalidomide-based PROTACs as degraders of endogenous KRAS G12C with potent anticancer activity
Ling Li et al.
BIOORGANIC CHEMISTRY (2021)
Orelabrutinib: First Approval
Sohita Dhillon
DRUGS (2021)
The protective effect of Geniposide on diabetic cognitive impairment through BTK/TLR4/NF-κB pathway
Shengnan Liu et al.
PSYCHOPHARMACOLOGY (2020)
Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1
Binbin Cheng et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Novel mouse model resistant to irreversible BTK inhibitors: a tool identifying new therapeutic targets and side effects
H. Yesid Estupinan et al.
BLOOD ADVANCES (2020)
Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry
Wen-Hao Guo et al.
NATURE COMMUNICATIONS (2020)
STAT3 Activation in Combination with NF-KappaB Inhibition Induces Tolerogenic Dendritic Cells with High Therapeutic Potential to Attenuate Collagen-Induced Arthritis
Carolina Prado et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2019)
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase
Yunhang Guo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases
Richard D. Caldwell et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation
Alexandru D. Buhimschi et al.
BIOCHEMISTRY (2018)
PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies
Yonghui Sun et al.
CELL RESEARCH (2018)
Inhibitor of Breton's tyrosine kinases, PCI-32765, decreases pro-inflammatory mediators' production in high glucose-induced macrophages
Zhe Fan et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Discovery of Novel Small-Molecule Inhibitors of NF-κB Signaling with Antiinflammatory and Anticancer Properties
Lei Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Inflammasome-Derived Exosomes Activate NF-kappa B Signaling in Macrophages
Yuehui Zhang et al.
JOURNAL OF PROTEOME RESEARCH (2017)
Bruton's tyrosine kinase inhibitors in B-cell lymphoma: current experience and future perspectives
T. Seiler et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
NF-kappa B signaling in inflammation
Ting Liu et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2017)
Phagocytosis-dependent activation of a TLR9-BTK-calcineurin-NFAT pathway co-ordinates innate immunity to Aspergillus fumigatus
Susanne Herbst et al.
EMBO MOLECULAR MEDICINE (2015)
Structure-Based Drug Design of RN486, a Potent and Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis
Yan Lou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
Sarah E. M. Herman et al.
BLOOD (2011)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Targeted intracellular protein degradation induced by a small molecule: En route to chemical proteomics
Ashley R. Schneekloth et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2008)
Immune deficiency or hyperactivity-Nf-κb illuminates autoimmunity
Saparna Pai et al.
JOURNAL OF AUTOIMMUNITY (2008)
Bmx tyrosine kinase regulates TLR4-induced IL-6 production in human macrophages independently of p38 MAPK and NFκB activity
Christine D. Palmer et al.
BLOOD (2008)
Signaling by Toll-like receptors 8 and 9 requires Bruton's tyrosine kinase
Sarah L. Doyle et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Bruton's tyrosine kinase is involved in p65-mediated transactivation and phosphorylation of p65 on serine 536 during NFκB activation by lipopolysaccharide
SL Doyle et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Zymosan-induced generalized inflammation: Experimental studies into mechanisms leading to multiple organ dysfunction syndrome
TJH Volman et al.
SHOCK (2005)
Share Paper
